RXRX

Recursion Pharmaceuticals, Inc.

RXRX · CIK 1601830 · Annual (10-K) · Last 5 years

Financial Trends

Revenue$75M
20212025
Net Income−$645M
20212025
Operating CF−$372M
20212025
Free Cash Flow−$378M
20212025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Revenue$0.1B$0.1B$0.0B$0.0B$0.0B
Cost of Revenue$0.1B$0.0B$0.0B$0.0B—
Gross Profit—————
R&D Expense$0.5B$0.3B$0.2B$0.2B$0.1B
SG&A Expense—————
Operating Income$-0.6B$-0.5B$-0.4B$-0.2B$-0.2B
Net Income$-0.6B$-0.5B$-0.3B$-0.2B$-0.2B
EPS (Basic)$-1.44$-1.69$-1.58$-1.36$-1.49
EPS (Diluted)$-1.44$-1.69$-1.58$-1.36$-1.49

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Total Assets$1.5B$1.4B$0.7B$0.7B$0.6B
Current Assets$0.8B$0.7B$0.4B$0.6B$0.5B
Cash & Equivalents$0.7B$0.6B$0.4B$0.5B$0.3B
Total Liabilities$0.3B$0.4B$0.2B$0.2B$0.1B
Current Liabilities$0.1B$0.2B$0.1B$0.1B$0.0B
Stockholders' Equity$1.1B$1.0B$0.5B$0.5B$0.5B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Operating Cash Flow$-0.4B$-0.4B$-0.3B$-0.1B$-0.2B
Investing Cash Flow$-0.0B$0.3B$-0.0B$0.2B$-0.3B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.5B$0.3B$0.1B$0.2B$0.5B
← Companies